Kelonia, Kailera, pyschedelics and T cell engagers — a BioCentury podcast

Lilly’s $3.25B deal for CAR T company, obesity play’s bumper IPO and more

The past week has delivered the largest M&A deal ever for a private, venture-backed biopharma, the second-largest follow-on ever for a NASDAQ-traded biotech and what could soon become the largest biotech IPO ever on NASDAQ. On the latest BioCentury This Week, BioCentury’s analysts discuss the $3.25 billion takeout of in vivo CAR T company Kelonia Therapeutics Inc. by  Eli Lilly and Co. (NYSE:LLY), the market debut by obesity play Kailera Therapeutics Inc. (NASDAQ:KLRA) and an upsized follow-on by Revolution Medicines Inc. (NASDAQ:RVMD).

The analysts also discuss how autoimmune T cell engagers are diverging from their oncology roots and the potential implications of President Donald Trump’s executive order on psychedelic therapies.

BioCentury’s analysts also take time to remember Sofinnova Partners’ Denis Lucquin, father of French biotech.

This episode of the BioCentury This Week podcast was brought to you by IQVIA Biotech.